Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. Video-interview Ann Janssens, MD, PhD, about the final results of the CLL11 study demonstrating on
    overall survival benefit of obinutuzumab in combination with chlorambucil in patients with previously
    untreated CLL and comorbidities

2. Video-interview with prof. Frank Morschhauser about the results of the phase III RELEVANCE trial: efficacy and
    safety of lenalidomide + rituximab (R2) versus rituximab + chemotherapy, followed by rituximab maintenance,
   as first-line treatment for patients with follicular lymphoma

3. Quizartinib prolongs overall survival in patients with FLT3-internal tandem duplication–mutated relapsed/refractory
    AML in the phase III QuANTUM-R trial

4. ELOQUENT-3: Elotuzumab plus pomalidomide/dexamethasone (EPd) shows favorable results over Pd for treatment
    of relapsed/refractory multiple myeloma

5. Early PET-driven treatment de-escalation can safely guide subsequent treatment in patients with advanced
    Hodgkin lymphoma